The investigation effectiveness of YAZ for dysmenorrhea associated with adenomyosis
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Adenomyosis; Dysmenorrhoea
- Focus Therapeutic Use
- 18 Oct 2018 Status changed from recruiting to discontinued.
- 23 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 17 Oct 2014 New trial record